key: cord-0735414-jziy72vc authors: Porfidia, Angelo; Valeriani, Emanuele; Pola, Roberto; Porreca, Ettore; Rutjes, Anne W.S.; Di Nisio, Marcello title: Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis date: 2020-08-12 journal: Thromb Res DOI: 10.1016/j.thromres.2020.08.020 sha: 263ae556fb92ab6dd5ca0156830252ad04cae4e8 doc_id: 735414 cord_uid: jziy72vc BACKGROUND: Venous thromboembolism (VTE) may complicate the course of Coronavirus Disease 2019 (COVID-19). OBJECTIVES: To evaluate the incidence of VTE in patients with COVID-19. METHODS: MEDLINE, EMBASE, and PubMed were searched up to 24th June 2020 for studies that evaluated the incidence of VTE, including pulmonary embolism (PE) and/or deep vein thrombosis (DVT), in patients with COVID-19. Pooled proportions with corresponding 95% confidence intervals (CI) and prediction intervals (PI) were calculated by random-effect meta-analysis. RESULTS: 3487 patients from 30 studies were included. Based on very low-quality evidence due to heterogeneity and risk of bias, the incidence of VTE was 26% (95% PI, 6%–66%). PE with or without DVT occurred in 12% of patients (95% PI, 2%–46%) and DVT alone in 14% (95% PI, 1%–75%). Studies using standard algorithms for clinically suspected VTE reported PE in 13% of patients (95% PI, 2%–57%) and DVT in 6% (95% PI, 0%–60%), compared to 11% (95% PI, 2%–46%) and 24% (95% PI, 2%–85%) in studies using other diagnostic strategies or patient sampling. In patients admitted to intensive care units, VTE occurred in 24% (95% PI, 5%–66%), PE in 19% (95% PI, 6%–47%), and DVT alone in 7% (95% PI, 0%–69%). Corresponding values in general wards were respectively 9% (95% PI, 0%–94%), 4% (95% PI, 0%–100%), and 7% (95% CI, 1%–49%). CONCLUSIONS: VTE represents a frequent complication in hospitalized COVID-19 patients and often occurs as PE. The threshold for clinical suspicion should be low to trigger prompt diagnostic testing. VTE, type and clinical presentation of VTE (symptomatic or incidentally detected pulmonary embolism [PE] or deep vein thrombosis [DVT] ). Any disagreement was resolved by consensus between the two review authors or by involving a third review author. The primary outcome of interest was VTE which included objectively diagnosed fatal or non-fatal PE and DVT of the upper or lower limbs. Secondary outcomes were PE with or without DVT, and DVT alone. The risk of bias for observational studies was evaluated with the methodological index for nonrandomized studies (MINORS), while the Cochrane tool was used to evaluate the quality of RCTs. [12, 13] The MINORS tool considers eight quality items which may be deemed as adequate, inadequate, or unclear. [12] The item related to the endpoint definition was considered appropriate if type of VTE and diagnostic protocol used in the study were clearly specified. Follow-up duration was considered adequate if the occurrence of VTE was assessed in all patients included in the study until hospital discharge or death. Categorical variables were described as counts and percentages and continuous variables presented as median (interquartile range) or mean (standard deviation), as appropriate. For meta-analytical purposes, single proportions were logit transformed to maintain symmetry. Summary estimates with the corresponding 95% prediction interval (PI) and 95% confidence interval (CI) were calculated by random-effect meta-analysis. The Wilson score was used to estimate CIs for the individual studies. to analyse the incidence of VTE according to dose of pharmacological prophylaxis, if data were available. Statistical analyses were performed using R studio version 1.2.5001, "meta" and "forest" packages. [16] A total of 1381 records were identified from the database search ( Figure 1 ). After removing 530 duplicates, 812 records were excluded by title and abstract screening. Of the remaining 39 studies evaluated as full-text, 30 were included with a total of 3487 patients. The inter-reviewer agreement was excellent with a kappa statistic of 0.90. [17] The size of the included studies ranged from 12 to 400 patients (Table 1) . Four studies were prospective, 22 retrospective, and in 4 the study design was unclear. Twenty-four studies were conducted in Europe, three in China, and three in the United States. Figure 2 shows the summary risk of bias. Sixteen studies (70.0%) included patients consecutively and none had adequate followup duration with 33.7% of patients (499/1480; 11 studies) still hospitalized at the end of the study. The mean age ranged between 57 and 70 years and 62.1% were males (1951/3144; 25 studies Figure 3 ), including PE with or without DVT in 12% (95% PI, 2% to 46%; 386/2908 patients; 22 studies, Figure 4 ) and DVT alone in 14% (95% PI, 1% to 75%; 347/2672 patients; 23 J o u r n a l P r e -p r o o f Journal Pre-proof studies, Figure 5 ). Fourteen studies reported information on the extension of PE which involved the main trunk or lobar pulmonary arteries in 37.8% of cases (91/241; 12 studies), segmental arteries in 37.9% (114/301; 12 studies) , and subsegmental arteries in 19.0% (59/311; 13 studies). Thirteen studies reported on the extension of DVT which involved the proximal veins in 32.2% of cases (88/273; 13 studies) and distal veins in 67.0% (136/203; 9 studies). Nine studies failed to describe the diagnostic work-up for VTE, 9 studies used imaging tests in case of clinically suspected VTE, and the remaining 12 studies used various approaches which included (serial) screening ultrasonography or patient sampling based on the availability of chest computed tomography independently of VTE suspicion. In studies which applied diagnostic tests only if thrombosis was clinically suspected, VTE was diagnosed in 17% (95% PI, 2% to 71%), PE with or without DVT in 13% (95% PI, 2% to 57%), and DVT alone in 6% (95% PI, 0% to 60%). Higher estimates for VTE and DVT alone were reported in studies using other diagnostic work-up or patient sampling ( Figures 3 and 5 ). Ten studies which performed screening ultrasonography for DVT in all patients found a DVT incidence that varied widely between 0% and 85% and seemed to be largely accounted by asymptomatic distal DVT. [10, 18] In the analysis restricted to studies in ICU patients where referral to imaging was based on clinical suspicion, VTE was diagnosed in 24% (95% PI, 5% to 66%; 7 studies), PE with or without DVT in 19% (95% PI, 6% to 47%; 10 studies), and DVT alone in 7% (95% PI, 0% to 69%; 6 studies, Supplementary Figure 1 ). The corresponding values in patients admitted to general wards were 9% (95% PI, 0% to 94%; 4 studies), 4% (95% PI, 0% to 100%; 3 studies), and 7% (95% CI, The incidence of VTE in hospitalized COVID-19 patients appears to be considerably higher compared to the incidence reported in previous studies on acute medical patients and critically-ill patients with sepsis or septic shock. [19] [20] [21] Most cases of VTE were represented by PE with or without concomitant DVT. The combination of systemic activation of coagulation, extensive pulmonary endotheliopathy and thrombo-inflammatory process caused by SARS-CoV2 may result in diffuse pulmonary intravascular coagulopathy and pulmonary arterial thrombosis. [22] [23] [24] The clinical presentation of PE may overlap with that of COVID-19 pneumonia which may hindrance the recognition of PE symptoms in patients who are already complaining of dyspnoea. Therefore, current estimates may even represent an underestimation of the actual PE incidence in COVID-19 as also suggested by autopsy studies. [25] Nine studies followed standard diagnostic protocols for suspected VTE, which included imaging tests performed only in cases of clinical suspicion or sudden increase in D-dimer levels. Although the incidence of VTE appeared to be lower compared to studies using other diagnostic strategies or patient sampling, the risk of VTE remained substantial with an average PE incidence that was as high as 19% in patients admitted to ICU. The risk of VTE seemed to remain considerable despite most patients received pharmacological thromboprophylaxis. [7] In all studies the decision on the intensity and duration of anticoagulation for VTE prevention was left to treating physicians limiting any conclusion about optimal dosing in these patients. Whether higher doses of thromboprophylaxis may reduce VTE without significantly increase the risk of major bleeding is currently under evaluation in several RCTs (NCT04345848, The proportion of patients who were still in hospital at the end of the study varied between 8% and 75.5%. As the risk of VTE may persist beyond the first week of hospitalization, inadequate followup duration may have contributed to underestimating VTE incidence. Pooled incidences are based on very low-quality evidence due to heterogeneity and risk of bias which reduces the confidence in the size of the estimates. Nevertheless, VTE incidence appears to be high, and referral to imaging may be advisable at a low threshold for VTE suspicion. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Covid-Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Venous Thromboembolism in Critically Ill Patients with Covid-19: Results of a Screening Study for Deep Vein Thrombosis COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2 Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis Pulmonary embolism in patients with Covid-19 pneumonia Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Systematic Screening for Venous Thromboembolic Events in COVID-19 Pneumonia COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease Incidence of venous thromboembolism in hospitalized patients with COVID-19 Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) Patients: Awareness of an Increased Prevalence. Circulation Acute Pulmonary Embolism and COVID-19 High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome